LC
BPMC

Lindbrook Capital’s Blueprint Medicines BPMC Stock Holding History

Lindbrook Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$27.4K Buy
309
+9
+3% +$878 ﹤0.01% 1220
2024
Q4 		$26.2K Buy
300
+1
+0.3% +$92 ﹤0.01% 1130
2024
Q3 		$27.7K Sell
299
-14
-4% -$1.39K ﹤0.01% 1114
2024
Q2 		$33.7K Sell
313
-38
-11% -$3.8K ﹤0.01% 969
2024
Q1 		$33.3K Buy
351
+9
+3% +$772 ﹤0.01% 958
2023
Q4 		$31.5K Sell
342
-38
-10% -$2.46K ﹤0.01% 959
2023
Q3 		$19.1K Buy
380
+7
+2% +$374 ﹤0.01% 1080
2023
Q2 		$23.6K Buy
373
+59
+19% +$3.21K ﹤0.01% 1002
2023
Q1 		$14.1K Buy
314
+189
+151% +$8.51K ﹤0.01% 1240
2022
Q4 		$5.48K Sell
125
-170
-58% -$8.15K ﹤0.01% 1775
2022
Q3 		$19K Hold
295
– – ﹤0.01% 997
2022
Q2 		$15K Sell
295
-13
-4% -$762 ﹤0.01% 1084
2022
Q1 		$20K Sell
308
-649
-68% -$46.6K ﹤0.01% 994
2021
Q4 		$103K Buy
957
+956
+95,600% +$100K 0.02% 483
2021
Q3 		$0 Sell
1
-23
-96% -$2.14K ﹤0.01% 1864
2021
Q2 		$2K Buy
24
+1
+4% +$92 ﹤0.01% 1559
2021
Q1 		$2K Buy
23
+8
+53% +$799 ﹤0.01% 1522
2020
Q4 		$2K Buy
+15
New +$1.58K ﹤0.01% 1426

Other funds holding BPMC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Lindbrook Capital's BPMC Position: Q1 2025 in Review

Lindbrook Capital increased its Blueprint Medicines (BPMC) stake by 3% in Q1 2025, buying an estimated $878 and bringing the position to 309 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1220.

Lindbrook Capital first reported a position in BPMC in Q4 2020 and has held it in 18 quarters since. The position peaked at $103K in Q4 2021. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Lindbrook Capital held 309 shares of Blueprint Medicines worth $27.4K as of Q1 2025.
  • Lindbrook Capital bought 9 Blueprint Medicines shares in Q1 2025, an estimated $878.
  • Blueprint Medicines made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1220 holding.
  • Lindbrook Capital first reported a position in Blueprint Medicines in Q4 2020 and has held it in 18 quarters since.
  • Lindbrook Capital's Blueprint Medicines position peaked at $103K in Q4 2021.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.